lolcde

LolCDE-IN-1, an inhibitor of the Lol proteins (LolCDE) complex, exhibits antibacterial activity.

LolCDE-IN-2 is a potent inhibitor of the Lol protein (LolCDE) and demonstrates antibacterial activity against E. coli MG1655, with a minimum inhibitory concentration (MIC) of 2 μg/ml [1].

LolCDE-IN-4 (Compound 1) demonstrates antibacterial potency by inhibiting the LolCDE complex and disrupting the release of lipoproteins from the inner membrane, showing efficacy against gram-negative bacteria such as Escherichia coli (MIC of 0.25-32 µg/ml) and Haemophilus influenzae.

G0507 is a pyrrolopyrimidinedione compound that serves as a potent inhibitor of Escherichia coli growth, effectively inducing the extracytoplasmic σE stress response. It acts as a valuable chemical probe, specifically designed to dissect lipoprotein trafficking in Gram-negative bacteria. Notably, G0507 demonstrates strong inhibitory activity against the LolCDE ABC Transporter.

Lolamicin is a Gram-negative selective antibiotic targeting the lipoprotein transport system LolCDE complex. It exhibits activity against over 130 multidrug-resistant clinical isolates, improves survival rates in mouse models of septicemia and pneumonia, and protects the gut microbiota.